Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

Summary

This phase 2, dose-finding trial evaluated retatrutide, a novel triple agonist of GIP, GLP-1, and glucagon receptors, in 338 adults with obesity over 48 weeks. Retatrutide at the highest dose (12 mg) produced a mean body weight reduction of 24.2%, the largest reduction reported for any anti-obesity medication in a clinical trial at the time of publication.

Key Findings

• Mean percentage change in body weight at 48 weeks was -24.2% at the highest dose (12 mg) vs -2.1% with placebo
• 100% of participants receiving the 12 mg dose achieved at least 5% weight loss, and 83% achieved at least 15% weight loss
• Retatrutide demonstrated dose-dependent improvements in glycemic parameters, lipid levels, and liver fat content